CRTX Cortexyme Inc.

58.64
-3.98  -6%
Previous Close 62.62
Open 63.29
Price To Book 12.37
Market Cap 1,574,629,603
Shares 26,852,483
Volume 116,445
Short Ratio
Av. Daily Volume 207,159
Stock charts supplied by TradingView

NewsSee all news

  1. Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer's Disease

     – Open-label extension study will provide COR388 to patients for an additional 48 weeks – GAIN Trial to continue as planned following pre-specified DMC safety data review Cortexyme, Inc. (NASDAQ:CRTX), a clinical

  2. Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

    – Corporate presentation by CEO Casey Lynch will be webcast live – Lynch will also participate in a roundtable session earlier in the day Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company

  3. Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer's Disease

    – In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer's – –The drug's target, the gingipains from P. gingivalis bacteria, preferentially attack the

  4. Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  5. Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer's disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 top-line data due 4Q 2021.
COR388 - GAIN
Alzheimer’s disease

Latest News

  1. Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer's Disease

     – Open-label extension study will provide COR388 to patients for an additional 48 weeks – GAIN Trial to continue as planned following pre-specified DMC safety data review Cortexyme, Inc. (NASDAQ:CRTX), a clinical

  2. Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020

    – Corporate presentation by CEO Casey Lynch will be webcast live – Lynch will also participate in a roundtable session earlier in the day Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company

  3. Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer's Disease

    – In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer's – –The drug's target, the gingipains from P. gingivalis bacteria, preferentially attack the

  4. Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019

    -- Presentation to be webcast on Cortexyme's website -- Cortexyme, Inc. (NASDAQ:CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to

  5. Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

    — Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer's disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial

  6. Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

    - Presentation will detail impact of Cortexyme's lead compound, COR388, on ApoE in Alzheimer's Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme's new investigational

  7. Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

    - International study is evaluating whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt the progression of Alzheimer's disease - GAIN Trial opened for U.S. enrollment in Q2 2019